Rx for Biotech cover art

All Episodes

Rx for Biotech — 86 episodes

#
Title
1

Why Fertility Care Needs to Change - And How Technology Can Help

2

The Future of Multiple Sclerosis Treatment: New Hope for MS Patients | Jason Tardio, Immunic

3

What If Your Own Cells Could Cure Cancer? CAR-T Therapy Explained

4

The Future of Brain Cancer Care: Combining Diagnostics and Targeted Radiation Therapy

5

How Targeted Chemotherapy and Immunotherapy are Changing Cancer Care

6

The Future of Precision Medicine: How Biomarkers Can Guide Your Treatment

7

How Novartis is Changing Cancer Treatment and Putting Patients First in Modern Cancer Care

8

Fixing the Body's Shield: A New Way to Fight Neurodegenerative Diseases

9

How to Advocate for Yourself in Cancer Care: Insights from a Top Oncologist

10

A New Hope for Skin Cancer: The Story Behind a Promising Immunotherapy

11

Targeting the Fire Within: How InflaRx Is Redefining Inflammation Control

12

How Novel Genetic Medicines may improve treatment of chronic Neurological Diseases

13

Restoring Breath: Biologic Innovation for the Most Vulenerable Patients

14

Reprogramming Immunity: How CCR5 Blockade Could Redefine Cancer Therapy

15

The Alpha Edge: Perspective Therapeutics on the Future of Theranostics and Radiopharmaceutical Therapies

16

Harnessing the Immune System: PDS Biotech’s NextGen Approach to Cancer Treatment

17

How Nonacus is Changing Cancer Detection with CEO, Jeff Bousfield

18

Hope in Hard Places: A Potential New Option for Patients with Pancreatic Cancer

19

How Mesenchymal Stem Cells Are Shaping the Future of Medicine with Dr. Kilian Kelly

20

Patient Perspective with CAR-T Cell Therapy Advocate, Brad Watt

21

How AI is Transforming Job Search and Recruiting in Life Sciences and Technology

22

From Nigeria to the USA: Gene Therapy Journey with Sickle Cell Warrior, Jimi Olaghere

23

The Promise of Dendritic Cell Vaccines with Diakonos Oncology President and COO Jay Hartenbach

24

New Therapies for Brain Cancer with Neurosurgeon Thomas Chen, CEO of NeOnc

25

From Meditation to Music: Exploring AI's Boundless Potential with Sreekanth Gopi

26

How Arvinas is Transforming Cancer and Neuroscience Therapies: An Interview with CBO, Randy Teel, PhD

27

The Future of Healthcare: Insights from the Biggest Health Tech Conference of 2024

28

How NGGT is Pioneering the Next Wave of Gene Therapies

29

Unlocking the Power of IL-2 with Aulos CEO, Aron Knickerbocker

30

Left Behind: Addressing Health Equity for the Rare Disease Patient Community

31

Emerging Cell Therapies for Blood Cancers with Arcellx CMO, Chris Heery, MD

32

Unlocking AI In Oncology with James Zou, PhD

33

Revolutioning Patient Access: An Interview with Genoplex CTO, Shoukri Kattan

34

Building a Leading Cell Therapy Service Line with Robb Richards - Penn Medicine

35

How MedStack helps Health Tech companies with Compliance and Data Privacy

36

How NervGen is Developing Novel Treatments to Repair Damage to the Nervous System

37

ASCO 2024 Recap, ADCs, Cell Therapies and RLTs

38

ASGCT 2024 Abstracts Preview

39

Update on Evolving Tech and Data Standards to Improve Cell Therapy Informatics

40

How Ryght is Building a Generative AI Platform for BioPharma

41

Revolutionizing Genetic Counseling: A Conversation with Igentify CEO, Doron Behar

42

ASGCT Annual Meeting Preview

43

2024 Biopharma Investment Outlook with Chris Dokomajilar

44

How one Survivor beat the odds against Mucosal Melanoma

45

Mark Carbone on How Respiratory Muscle Training can improve Cardiopulmonary Outcomes

46

Episode 2: Future Advances in Cell Therapy Analytics

47

Episode 1: Current Advancements in Cell Therapy Analytics

48

Health Policy Update: IRA, 340b Drug Pricing and PBMs

49

Special Episode: ASGCT Policy Summit Highlights

50

The IRA 1-year Anniversary Episode: What Lies Ahead?

51

Developing Best-in-Class Radiopharmaceuticals for Cancer Patients

52

ASGCT Policy Summit Preview

53

How ChromaCode is Accelerating Biomarker Testing to Improve Patient Outcomes

54

How Medicenna is Developing "Superkines" as Novel Immunotherapies

55

How Virax Biolabs is Developing a Potentially Game-Changing Immunology Platform for T-Cell Testing

56

Novel Immunotherapy approaches to engaging the Innate Immune System

57

Emerging Therapies for Rare Genetic Mitochondrial Diseases

58

Harnessing the Cell Cycle to Treat Cancer and other Serious Diseases

59

American Society of Gene and Cell Therapy Meeting Highlights

60

Emerging PSMA Targeted Radioantibody Therapies for Prostate Cancer with CEO, Philip Kantoff, MD

61

Progress in Developing Fibroblast Cell Therapies with FibroBiologics CEO, Pete O'Heeron

62

Erandi De Silva, PhD on Building a Gene Therapy Pipeline and Culture

63

Gene Therapy Landscape Trends: An Interview with Forge Biologics CEO, Tim Miller, PhD

64

AACR 2023 Preview

65

New Therapies for Kidney Disease with XORTX Therapeutics CEO, Allen Davidoff, PhD

66

FDA AMAT for Regenerative Medicine Therapies Workshop Recap

67

Don Davis, PhD, MBA on Challenges in Scaling Life Science Companies

68

Applications of AI and Machine Learning in BioPharma and Healthcare

69

A Look Ahead to 2023 Biopharma M&A, Venture Financing, Licensing and Partnerships

70

Biopharma Products and Companies to Watch in 2023

71

American Society of Hematology Highlights

72

Role of oxMIF in Innate and Adaptive Immunity with OncoOne CBO, Brent Meadows

73

How to Improve Customer Engagement in 2023

74

Next Generation Non-Viral Gene Therapies with Cove Therapeutics CEO, Niren Shah

75

Meeting on the Mesa Roundtable Part 2: Applying "A-Cell" Concepts when Developing Cell Therapies

76

Meeting on the Mesa Roundtable Part 1: 'A-Cell' Principles of Quality by Design

77

IRA Impact on Biopharma Drug Development

78

OTAT Townhall Insights for Developers of Gene Therapies

79

Insights into the Cell and Gene Therapy Landscape

80

Medical Communications after the Pandemic

81

Best Practices in Market Access, Trade and Distribution

82

Chandra Ramanathan, PhD on How to Create Value through Innovation Ecosystems

83

Chris Dokomajilar on Trends in Life Science Investing, M&A and Partnering

84

CRISPR and Gene Editing for Human Disease

85

The Future of Cell and Gene Therapies

86

Regulatory Challenges in Biotech